[go: up one dir, main page]

NZ600051A - Method of providing disease-specific binding molecules and targets - Google Patents

Method of providing disease-specific binding molecules and targets

Info

Publication number
NZ600051A
NZ600051A NZ600051A NZ60005108A NZ600051A NZ 600051 A NZ600051 A NZ 600051A NZ 600051 A NZ600051 A NZ 600051A NZ 60005108 A NZ60005108 A NZ 60005108A NZ 600051 A NZ600051 A NZ 600051A
Authority
NZ
New Zealand
Prior art keywords
seq
amino acid
acid sequence
targets
specific binding
Prior art date
Application number
NZ600051A
Inventor
Roger Nitsch
Christoph Hock
Christoph Esslinger
Marlen Knobloch
Kathrin Tissot
Jan Grimm
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of NZ600051A publication Critical patent/NZ600051A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

600051 Disclosed is an isolated human antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL) each comprising three complementarity determining regions (CDRs), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 20 (SYGMH), the VH CDR2 (VIWFDGTKKYYTDSVKG) comprises the amino acid sequence of SEQ ID NO: 21 (DRGIGARRGPYYMDV), the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 22, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 23 (RASQSISSYLN), the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 24 (AASSLQS), and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 25 (QQSYSTPLT).
NZ600051A 2007-01-05 2008-01-07 Method of providing disease-specific binding molecules and targets NZ600051A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87883107P 2007-01-05 2007-01-05
EP07000211 2007-01-05
US93429107P 2007-06-11 2007-06-11
EP07020341 2007-10-17
NZ57788308 2008-01-07

Publications (1)

Publication Number Publication Date
NZ600051A true NZ600051A (en) 2014-01-31

Family

ID=50619562

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600051A NZ600051A (en) 2007-01-05 2008-01-07 Method of providing disease-specific binding molecules and targets

Country Status (1)

Country Link
NZ (1) NZ600051A (en)

Similar Documents

Publication Publication Date Title
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
NZ581512A (en) Rsv-specific binding molecules and means for producing them
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
HRP20191462T1 (en) Antibodies directed to her-3 and uses thereof
WO2006103100A3 (en) Antibodies against ccr5 and uses thereof
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
MY200988A (en) CD3 Binding Antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
GEP20074222B (en) Antibodies to cd40
NZ599148A (en) Rsv-specific binding molecule
NZ626269A (en) Anti-phf-tau antibodies and their uses
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
HRP20201022T1 (en) COMPLETE HUMAN ANTIBODY AGAINST HUMAN CD137 AND ITS USE
NO20090877L (en) Antibodies targeting alpha Vbeta6 and its applications
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ602020A (en) Anti-cd40 antibodies
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
WO2006039258A3 (en) Human antibodies against parathyroid hormone
NZ611269A (en) Neutralizing anti-ccl20 antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 JAN 2015 BY CULLENS

Effective date: 20140507

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2016 BY COMPUTER PACKAGES INC

Effective date: 20141218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20151218

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161220

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2019 BY RENEWALS TEAM

Effective date: 20171216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2020 BY RENEWALS TEAM

Effective date: 20181113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2021 BY CPA GLOBAL

Effective date: 20200117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2022 BY CPA GLOBAL

Effective date: 20210107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2023 BY CPA GLOBAL

Effective date: 20211202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2024 BY ANAQUA SERVICES

Effective date: 20221221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2025 BY ANAQUA SERVICES

Effective date: 20231219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2026 BY PAVIS PAYMENTS GMBH

Effective date: 20241230